These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33275060)

  • 21. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].
    Geng CY; Yang GZ; Wang HJ; Zhou HX; Zhang ZY; Jian Y; Chen WM
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):164-171. PubMed ID: 35090251
    [No Abstract]   [Full Text] [Related]  

  • 23. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
    González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
    Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between Clinical Factors and Prognosis in Newly Diagnosed Multiple Myeloma.
    Zhao XQ; Zhao SY; Chen WX; Liu XW; Yan HX; Lou YJ
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):601-605. PubMed ID: 32703344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
    Kastritis E; Zagouri F; Symeonidis A; Roussou M; Sioni A; Pouli A; Delimpasi S; Katodritou E; Michalis E; Michael M; Hatzimichael E; Vassou A; Repousis P; Christophoridou A; Kartasis Z; Stefanoudaki E; Megalakaki C; Giannouli S; Kyrtsonis MC; Konstantopoulos K; Spyroupoulou-Vlachou M; Terpos E; Dimopoulos MA;
    Leukemia; 2014 Oct; 28(10):2075-9. PubMed ID: 24637336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.
    Fan L; Hong J; Huang H; Fu D; Wu S; Wang Q; Ye Y; Liu Y
    Med Sci Monit; 2017 May; 23():2636-2643. PubMed ID: 28557972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
    Guo R; Shen XX; Xia Y; Jin YY; Li JY; Chen LJ; Qiu HR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):768-773. PubMed ID: 38926965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients.
    Zhang X; Yang J; Chen S; Liu C; Wang Z; Ren H; Zhou L
    J Thromb Thrombolysis; 2022 Oct; 54(3):542-549. PubMed ID: 35445377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of the controlling nutritional status score in patients with multiple myeloma.
    Kamiya T; Ito C; Fujita Y; Ogura S; Mizuno K; Sakurai A; Aisa Y; Nakazato T
    Leuk Lymphoma; 2020 Aug; 61(8):1894-1900. PubMed ID: 32306801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma.
    Kyrtsonis MC; Repa C; Dedoussis GV; Mouzaki A; Simeonidis A; Stamatelou M; Maniatis A
    Med Oncol; 1998 Jul; 15(2):124-8. PubMed ID: 9789221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.
    Muchtar E; Dispenzieri A; Kumar SK; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
    Haematologica; 2016 Sep; 101(9):1102-9. PubMed ID: 27479823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
    Atrash S; Robinson M; Taneja A; Paul B; Cassetta K; Ndiaye A; Varga C; Block J; Lipford EH; Smith ET; McCall CM; Thurston V; Foureau D; Usmani SZ; Voorhees PM; Bhutani M
    Eur J Haematol; 2023 Sep; 111(3):373-381. PubMed ID: 37311695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.
    Zhang L; Chen S; Huang M; Wang W; Liang Y; Wang Y
    Ann Hematol; 2023 Jan; 102(1):125-132. PubMed ID: 36441260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Baseline
    Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
    Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma.
    Ning X; Wei X; Chen B; Li Z; Zheng Z; Yi Z; Wei Q; Guo X; Kang Q; Feng R; Wei Y
    Leuk Lymphoma; 2022 Nov; 63(11):2573-2578. PubMed ID: 35819872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
    Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
    [No Abstract]   [Full Text] [Related]  

  • 39. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
    Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.